These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34648119)

  • 1. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
    Schoenbeck KL; Flynn KE
    Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.
    Efficace F; Iurlo A; Patriarca A; Stagno F; Bee PC; Ector G; Capodanno I; Elena C; Bonifacio M; Blijlevens NMA; Caocci G; Wan C; Abruzzese E; Breccia M; Cottone F; Okumura I; Oerlemans S; Cascavilla N; Albano F; Kota V; Sztankay M; Miggiano MC; Saussele S; Di Renzo N; Sorà F; Castagnetti F; Baccarani M; Vignetti M; Rosti G
    Leuk Lymphoma; 2021 Mar; 62(3):669-678. PubMed ID: 33153355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
    Efficace F; Stagno F; Iurlo A; Breccia M; Cottone F; Bonifacio M; Abruzzese E; Castagnetti F; Caocci G; Crugnola M; Capodanno I; Martino B; Tiribelli M; Patriarca A; Gozzini A; Pregno P; Saussele S; Cascavilla N; Fozza C; Bergamaschi M; Binotto G; Vignetti M; Rosti G
    Leukemia; 2020 Feb; 34(2):488-498. PubMed ID: 31477798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Efficace F; Vignetti M; Sparano F; Scalzulli E; Breccia M
    Expert Rev Hematol; 2021 Mar; 14(3):293-302. PubMed ID: 33554672
    [No Abstract]   [Full Text] [Related]  

  • 6. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy].
    Yu L; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):533-539. PubMed ID: 30122010
    [No Abstract]   [Full Text] [Related]  

  • 8. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Efficace F; Castagnetti F; Martino B; Breccia M; D'Adda M; Angelucci E; Stagno F; Cottone F; Malato A; Trabacchi E; Capalbo SF; Gobbi M; Visani G; Salvucci M; Capodanno I; Tosi P; Tiribelli M; Scortechini AR; Levato L; Maino E; Binotto G; Gugliotta G; Vignetti M; Baccarani M; Rosti G
    Cancer; 2018 May; 124(10):2228-2237. PubMed ID: 29499087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.
    Efficace F; Baccarani M; Breccia M; Saussele S; Abel G; Caocci G; Guilhot F; Cocks K; Naeem A; Sprangers M; Oerlemans S; Chie W; Castagnetti F; Bombaci F; Sharf G; Cardoni A; Noens L; Pallua S; Salvucci M; Nicolatou-Galitis O; Rosti G; Mandelli F
    Qual Life Res; 2014 Apr; 23(3):825-36. PubMed ID: 24026634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic disease management practices and factors associated with health-related quality-of-life for persons with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Zhang Q; Li Z; Hou Y; Dang H; Chen J; Liang L; Wang Q; Cao C; Zhao H; Gui R; Zu Y; Zhou J; Yu F; Wang J; Song Y; Zhang Y
    Ann Palliat Med; 2022 Apr; 11(4):1336-1350. PubMed ID: 35523742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
    Efficace F; Mahon FX; Richter J; Piciocchi A; Cipriani M; Nicolini FE; Mayer J; Zackova D; Janssen JJWM; Panayiotidis P; Vestergaard H; Koskenvesa P; Almeida A; Hjorth-Hansen H; Martinez-Lopez J; Olsson-Strömberg U; Hochhaus A; Berger MG; Etienne G; Klamova H; Faber E; Rousselot P; Pfirrmann M; Saussele S
    Leukemia; 2024 Aug; 38(8):1722-1730. PubMed ID: 38987274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
    Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.
    Bostan H; Toptas T; Tanrikulu FP; Kut K; Arikan F; Yilmaz F; Atagunduz I; Firatli-Tuglular T
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):836-842. PubMed ID: 32958432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How could patient reported outcomes improve patient management in chronic myeloid leukemia?
    De Marchi F; Medeot M; Fanin R; Tiribelli M
    Expert Rev Hematol; 2017 Jan; 10(1):9-14. PubMed ID: 27858461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
    Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
    Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
    Kantarjian HM; Mamolo CM; Gambacorti-Passerini C; Cortes JE; Brümmendorf TH; Su Y; Reisman AL; Shapiro M; Lipton JH
    Cancer; 2018 Feb; 124(3):587-595. PubMed ID: 29072772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
    Réa D; Boquimpani C; Mauro MJ; Minami Y; Allepuz A; Maheshwari VK; D'Alessio D; Wu Y; Lawrance R; Narbutas S; Sharf G; Hochhaus A
    Leukemia; 2023 May; 37(5):1060-1067. PubMed ID: 37069326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
    Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
    Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.
    Efficace F; Cardoni A; Cottone F; Vignetti M; Mandelli F
    Leuk Res; 2013 Feb; 37(2):206-13. PubMed ID: 23177797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.